ERBB2 and breast cancer: In the HER2-negative breast cancer cohort treated with Bevacizumab, MMP2, COL5A2, COL6A1, DLK1, and MDK were identified as predictive of treatment response, aligning with their documented roles in angiogenesis and stromal interactions.